Atlas Genetics adds R&D expertise
This article was originally published in Clinica
Executive Summary
UK IVD firm Atlas Genetics has appointed Daniel Adlerstein director of research and development. Mr Adlerstein joins the Bath-based company from Diasorin, where he worked for over a decade and held various product development roles. These roles include building Diasorin’s molecular diagnostics program and developing molecular tests and instruments in infectious diseases and oncology. Mr Adlerstein’s knowledge in this area will come in handy in his new position at Atlas, which is developing ultra-rapid point-of-care tests for a range of infectious diseases.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.